Primus In News
Indian pharma companies grows footprint in US cancer generics market
16-04-2025
Nilaya Varma, Group CEO & Co-Founder, Primus Partners, highlighted the strong healthcare demand in the US, driven by rising drug prices and a push for affordable care. He emphasized that the Affordable Care Act has boosted access, increasing demand for generics and biosimilars. Additionally, US efforts to diversify supply chains away from China are opening doors for Indian pharmaceutical firms, which are leveraging their generics experience and gaining global approvals through strategic partnerships.
Explore Related Insights
- Frontier Markets’ Largest Women Empowerment Programme ‘She-Leads Bharat’ to Invest in 1MN Rural Women and 100MN Households of India
- Celebrity investors of start-ups
- Generative AI: The race where the ‘slowest’ wins
- JioHotstar taps influencers to turn Wimbledon into a lifestyle experience for India’s young consumers